Vaccines for established cancer: overcoming the challenges posed by immune evasion

doi:10.1038/nrc.2016.16

Review

. 2016 Apr;16(4):219-33.

doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11.

Vaccines for established cancer: overcoming the challenges posed by immune evasion

Sjoerd H van der Burg¹, Ramon Arens², Ferry Ossendorp², Thorbald van Hall¹, Cornelis J M Melief^{2

3}

Affiliations

¹ Department of Clinical Oncology, Leiden University Medical Center.
² Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
³ ISA Pharmaceuticals, J. H. Oortweg 19, 2333 CH, Leiden, The Netherlands.

PMID: 26965076
DOI: 10.1038/nrc.2016.16

Review

Vaccines for established cancer: overcoming the challenges posed by immune evasion

Sjoerd H van der Burg et al. Nat Rev Cancer. 2016 Apr.

. 2016 Apr;16(4):219-33.

doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11.

Authors

Sjoerd H van der Burg¹, Ramon Arens², Ferry Ossendorp², Thorbald van Hall¹, Cornelis J M Melief^{2

3}

Affiliations

¹ Department of Clinical Oncology, Leiden University Medical Center.
² Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
³ ISA Pharmaceuticals, J. H. Oortweg 19, 2333 CH, Leiden, The Netherlands.

PMID: 26965076
DOI: 10.1038/nrc.2016.16

Abstract

Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease, carcinoma in situ or minimal residual disease, therapeutic vaccination can be clinically successful as monotherapy; however, in established cancers, therapeutic vaccines will require co-treatments to overcome immune evasion and to become fully effective. In this Review, we discuss the progress that has been made in overcoming immune evasion controlled by tumour cell-intrinsic factors and the tumour microenvironment. We summarize how therapeutic benefit can be maximized in patients with established cancers by improving vaccine design and by using vaccines to increase the effects of standard chemotherapies, to establish and/or maintain tumour-specific T cells that are re-energized by checkpoint blockade and other therapies, and to sustain the antitumour response of adoptively transferred T cells.

PubMed Disclaimer

Cited by

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens.
Darrigrand R, Pierson A, Rouillon M, Renko D, Boulpicante M, Bouyssié D, Mouton-Barbosa E, Marcoux J, Garcia C, Ghosh M, Alami M, Apcher S. Darrigrand R, et al. Commun Biol. 2021 Mar 1;4(1):269. doi: 10.1038/s42003-021-01801-2. Commun Biol. 2021. PMID: 33649389 Free PMC article.
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy.
Beyranvand Nejad E, Labrie C, Abdulrahman Z, van Elsas MJ, Rademaker E, Kleinovink JW, van der Sluis TC, van Duikeren S, Teunisse AFAS, Jochemsen AG, Oosting J, de Miranda NFCC, Van Hall T, Arens R, van der Burg SH. Beyranvand Nejad E, et al. J Immunother Cancer. 2020 Sep;8(2):e001326. doi: 10.1136/jitc-2020-001326. J Immunother Cancer. 2020. PMID: 32873723 Free PMC article.
Artificially cloaked viral nanovaccine for cancer immunotherapy.
Fusciello M, Fontana F, Tähtinen S, Capasso C, Feola S, Martins B, Chiaro J, Peltonen K, Ylösmäki L, Ylösmäki E, Hamdan F, Kari OK, Ndika J, Alenius H, Urtti A, Hirvonen JT, Santos HA, Cerullo V. Fusciello M, et al. Nat Commun. 2019 Dec 17;10(1):5747. doi: 10.1038/s41467-019-13744-8. Nat Commun. 2019. PMID: 31848338 Free PMC article.
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.
Grippin AJ, Wummer B, Wildes T, Dyson K, Trivedi V, Yang C, Sebastian M, Mendez-Gomez HR, Padala S, Grubb M, Fillingim M, Monsalve A, Sayour EJ, Dobson J, Mitchell DA. Grippin AJ, et al. ACS Nano. 2019 Dec 24;13(12):13884-13898. doi: 10.1021/acsnano.9b05037. Epub 2019 Dec 2. ACS Nano. 2019. PMID: 31730332 Free PMC article.
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.
Ashi MO, Mami-Chouaib F, Corgnac S. Ashi MO, et al. Explor Target Antitumor Ther. 2022;3(6):746-762. doi: 10.37349/etat.2022.00111. Epub 2022 Dec 22. Explor Target Antitumor Ther. 2022. PMID: 36654823 Free PMC article. Review.

See all "Cited by" articles

References

1. Nature. 2007 Dec 6;450(7171):903-7 - PubMed
1. Semin Immunol. 2013 Apr;25(2):182-90 - PubMed
1. J Transl Med. 2013 Apr 04;11:88 - PubMed
1. Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500 - PubMed
1. Oncoimmunology. 2013 Dec 1;2(12):e27215 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Nature. 2007 Dec 6;450(7171):903-7 - PubMed

[2] Nature. 2007 Dec 6;450(7171):903-7 - PubMed

[3] Semin Immunol. 2013 Apr;25(2):182-90 - PubMed

[4] Semin Immunol. 2013 Apr;25(2):182-90 - PubMed

[5] J Transl Med. 2013 Apr 04;11:88 - PubMed

[6] J Transl Med. 2013 Apr 04;11:88 - PubMed

[7] Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500 - PubMed

[8] Pigment Cell Melanoma Res. 2015 Sep;28(5):490-500 - PubMed

[9] Oncoimmunology. 2013 Dec 1;2(12):e27215 - PubMed

[10] Oncoimmunology. 2013 Dec 1;2(12):e27215 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Vaccines for established cancer: overcoming the challenges posed by immune evasion

Affiliations

Vaccines for established cancer: overcoming the challenges posed by immune evasion

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources